- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02855554
Quantitative Cardiac Parametric Mapping (Myomapping)
November 3, 2025 updated by: Medical University of South Carolina
Novel Magnetic Resonance Imaging Techniques for Quantitative Cardiac Parametric Mapping
The overall goal of this project is to evaluate the clinical potential of fast quantitative myocardial tissue characterization using recently emerged Cardiac Magnetic Resonance Imaging (CMR) techniques to aid the diagnosis, treatment, and follow up of patients with myocardial diseases, such as ischemic heart disease, cardiomyopathies, and myocarditis.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
240
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Mark Ghent, BA
- Phone Number: 843-876-7148
- Email: ghent@musc.edu
Study Contact Backup
- Name: Jacob Rowe, BA
- Phone Number: 843-876-4922
- Email: roweja@musc.edu
Study Locations
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Recruiting
- Medical University of South Carolina
-
Contact:
- John Martinez, MS
- Phone Number: 843-876-7148
- Email: martjohn@musc.edu
-
Contact:
- Hunter Gray, BS
- Phone Number: 843-876-4922
- Email: grayhu@musc.edu
-
Principal Investigator:
- Akos Varga-Szemes, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Subject must be 18-90 years of age.
- Subject must be previously diagnosed with or suspected to have one of the following conditions.
- Myocardial ischemia or infarction (group 1)
- Hypertrophic cardiomyopathy (group 2)
- Infiltrative cardiomyopathy (group 3)
- Myocarditis (group 4)
- Subject must have been referred for a clinically indicated CMR.
Exclusion Criteria:
- Subject has any implanted device or condition in which an MR scan would be contraindicated.
- Subject has an acute psychiatric disorder or is cognitively impaired.
- Subject is using or is dependent on substances of abuse.
- Subject is unwilling to comply with the requirements of the protocol.
- Subject has previously entered this study.
- Subject has an allergy against MRI contrast agents.
- Subject is in acute unstable condition.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Additional 5 minute research MR scan of heart.
The purpose of this is to evaluate new, faster MR scans
|
Evaluation of clinical potential of fast quantitative myocardial tissue characterization using recently emerged CMRI techniques to aid the diagnosis, treatment, and follow up of patients with myocardial diseases.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Clinical value of fast T1, T2, and T2* mapping of the left ventricle for the assessment of necrosis/scar, edema, and possible intramyocardial hemorrhage in patients with heart disease.
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Akos Varga-Szemes, MD, Medical University of South Carolina
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 20, 2014
Primary Completion (Estimated)
December 1, 2026
Study Completion (Estimated)
December 1, 2026
Study Registration Dates
First Submitted
July 28, 2016
First Submitted That Met QC Criteria
August 1, 2016
First Posted (Estimated)
August 4, 2016
Study Record Updates
Last Update Posted (Estimated)
November 5, 2025
Last Update Submitted That Met QC Criteria
November 3, 2025
Last Verified
November 1, 2025
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00035552
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiomyopathy, Myocarditis, Ischemic Heart Disease
-
Fundacion para la Formacion e Investigacion Sanitarias...RecruitingMyocarditis Acute | Inflammatory CardiomyopathySpain
-
Theresien Hospital MannheimUniversity Hospital Heidelberg, GER; GRN Hospital Weinheim, GER; McGill University... and other collaboratorsRecruiting
-
Hospital Sao RafaelCompletedChronic Chagasic MyocarditisBrazil
-
Tongji HospitalTaihe Hospital; Wuhan Central HospitalRecruitingMyocarditis | Inflammatory CardiomyopathyChina
-
Chinese Academy of Medical Sciences, Fuwai HospitalEnrolling by invitationMyocarditis | Inflammatory Cardiomyopathy
-
Union Hospital, Tongji Medical College, Huazhong...Recruiting
-
Shanghai Zhongshan HospitalNot yet recruitingCardiovascular Diseases | Myocarditis | Cardiomyopathies | Ischemic Cardiomyopathy | Arrhythmogenic Right Ventricular Cardiomyopathy | Hypertrophic Cardiomyopathy (HCM) | Restrictive Cardiomyopathy | Amyloid Cardiomyopathy | Dilated Cardiomyopathy (DCM)
-
Zoll Medical CorporationRecruitingCardiovascular Diseases | Cardiomyopathies | Heart Disease, Ischemic | Cardiomyopathy IschemicGermany
-
Göteborg UniversitySahlgrenska University Hospital, SwedenEnrolling by invitationMyocarditis | Hypertrophic Cardiomyopathy | Arrhythmogenic Right Ventricular Cardiomyopathy | Restrictive Cardiomyopathy | Dilated Cardiomyopathies | Giant Cell Myocarditis | Amyloidosis; Heart (Manifestation) | Sarcoidosis With MyocarditisSweden
-
Genzyme, a Sanofi CompanyTerminatedIschemic Heart Disease | Ischemic Cardiomyopathy | Ischemic Heart FailureBelgium, France, Germany, Italy, Switzerland, United Kingdom
Clinical Trials on Cardiac Magnetic Resonance (CMR) imaging techniques
-
Chinese PLA General HospitalRecruitingST Segment Elevation Myocardial Infarction (STEMI) | Ventricular Dysfunction | Prognosis | Myocardial Infarction (MI) | Magnetic Resonance Imaging (MRI) | Heart Ventricles | Artificial Intelligence (AI)China
-
Ottawa Hospital Research InstituteOttawa Heart Institute Research CorporationCompleted
-
Weill Medical College of Cornell UniversityNational Heart, Lung, and Blood Institute (NHLBI)RecruitingMultivessel Coronary Artery Disease | Ischemic Left Ventricle Systolic DysfunctionUnited States, Canada, Austria, China, Serbia
-
University of AdelaideUppsala UniversityCompleted
-
Ottawa Heart Institute Research CorporationCanadian Institutes of Health Research (CIHR); The Finnish Funding Agency for...CompletedHeart FailureCanada, Finland
-
Universitätsmedizin MannheimCompletedCardiac DiseasesGermany
-
Beth Israel Deaconess Medical CenterDana-Farber Cancer Institute; American Heart AssociationCompleted
-
Society for Cardiovascular Magnetic ResonanceBayer; Siemens Medical SolutionsCompletedMyocardial IschemiaUnited States
-
Wake Forest University Health SciencesNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...CompletedChest Pain | Acute Coronary SyndromeUnited States
-
Second Affiliated Hospital, School of Medicine,...UnknownMyocardial Injury | Osteosarcoma | Cardiotoxicity | Doxorubicin Induced Cardiomyopathy | Chemotherapy Induced Systolic DysfunctionChina